P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI‐MYELOMA TREATMENTS ON POST‐ PROGRESSION OUTCOMES IN THE REAL‐WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE
Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis‐Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Labropoulou, Vasiliki, Pouli, Anastasia, Roussou, Maria, Gavriatopoulou, Maria, Verrou, Evgenia, Dimopoulos, Meletios A., Terpos, Evangelos
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE
Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Fotiou, Despina, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis‐Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Pouli, Anastasia, Migkou, Magdalini, Gavriatopoulou, Maria, Verrou, Evgenia, Christine Kyrtsonis, Marie, Dimopoulos, Meletios A., Terpos, Evangelos
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article